IL6 and acute kidney injury: AKI occurred in 34% of patients, but there were no differences between the two groups in the incidence or severity of AKI, increases in AKI biomarkers (cystatin C and neutrophil gelatinase-associated lipocalin) or increases in markers of inflammation (interleukin-6 and myeloperoxidase).